Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals

NCT06762730 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

HIV Infected Individuals
Osteopenia

Interventions

DRUG: Zoledronic Acid 5 mg/Bag 100 ml Inj

Sponsor

Hadassah Medical Organization

Collaborators

[object Object]
[object Object]